Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 4/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.35 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.35 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.34 |
| ▸ | CPA1 | P15085 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.34 |
| ▸ | FNTB | P49356 | 1/20 | 0.34 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7156162 | 0.85 | CYP19A1 (0.42) | HRH3CYP19A1DPP4PANK3CPA1 | |
| SCHEMBL7119884 | 0.84 | HRH3 (0.37) | HRH3CYP19A1PANK3CPA1RAB9A | |
| SCHEMBL7586233 | 0.82 | PRKAA2 (0.32) | HRH3CYP19A1DPP4DPP8PANK3 | |
| SCHEMBL7588753 | 0.81 | FNTA (0.55) | DPP8PANK3FNTAFNTBPGGT1B | |
| SCHEMBL7132213 | 0.81 | PDK2 (0.37) | HRH3CYP19A1DPP4PANK3PRKAA2 | |
| SCHEMBL7131139 | 0.81 | HRH3 (0.43) | HRH3CYP19A1DPP4PANK3PRKAA2 | |
| SCHEMBL7462788 | 0.81 | HRH3 (0.36) | HRH3CYP19A1DPP4DPP8PANK3 | |
| SCHEMBL7128974 | 0.81 | HRH3 (0.37) | HRH3CYP19A1DPP4DPP8PRKAA2 | |
| SCHEMBL7481462 | 0.81 | PRKAA2 (0.39) | HRH3CYP19A1PRKAA2FNTAFNTB | |
| SCHEMBL7467860 | 0.80 | HSD11B1 (0.41) | HRH3CYP19A1DPP4DPP8PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003524618-A | — | — | 2003-08-19 | — | — | JP | claimed |
| EP-1158982-A4 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2002-06-12 | — | — | EP | claimed |
| US-6376496-B1 | TREATMENT OF CANCER | MERCK & CO., INC. | 2002-04-23 | — | — | US | claimed |
| EP-1158982-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2001-12-05 | — | — | EP | claimed |
| WO-2001022963-A1 | METHOD OF PREVENTING OSTEOPOROSIS | MERCK & CO., INC. (US) | 2001-04-05 | — | — | WO | claimed |
| WO-2000052134-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | claimed |
| US-20020072081-A1 | Geranylgeranyl transferase inhibitor screening assay | ENG WAI-SI (US) | 2002-06-13 | — | — | US | disclosed |
| EP-1158982-A4 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6376496-B1 | TREATMENT OF CANCER | MERCK & CO., INC. | 2002-04-23 | — | — | US | disclosed |
| EP-1158982-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2001022963-A1 | METHOD OF PREVENTING OSTEOPOROSIS | MERCK & CO., INC. (US) | 2001-04-05 | — | — | WO | disclosed |
| WO-2000052134-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072081-A1 | Geranylgeranyl transferase inhibitor screening assay | GGT1, FNTA, GGPS1 | HRH3 4170/4885CYP19A1 2104/4885DPP4 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.